Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tomer Meirson

Showing results (1-10 of 56) with videos related to

Pageof 6
Sort By:
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|August 5, 2018
Targeting invadopodia for blocking breast cancer metastasisTomer Meirson, Hava Gil-Henn
Accountability in Research|July 2, 2021
The common sense behind clinical trial names: An empirical study of trial acronymsTomer Meirson, Gal Markel, David Bomze
Bioinformatics (Oxford, England)|August 21, 2020
Structural basis of SARS-CoV-2 spike protein induced by ACE2Tomer Meirson, David Bomze, Gal Markel
BMC Gastroenterology|November 18, 2024
Survival outcomes of population-wide colonoscopy screening: reanalysis of the NordICC dataTomer Meirson, Gal Markel, Daniel A Goldstein
Plos Computational Biology|December 22, 2016
Normal Modes Expose Active Sites in EnzymesYitav Glantz-Gashai, Tomer Meirson, Abraham O Samson
Drug Design, Development and Therapy|June 3, 2017
An in silico high-throughput screen identifies potential selective inhibitors for the non-receptor tyrosine kinase Pyk2Tomer Meirson, Abraham O Samson, Hava Gil-Henn
Bioinformatics (Oxford, England)|May 6, 2024
Peptriever: a Bi-Encoder approach for large-scale protein-peptide binding searchRoni Gurvich, Gal Markel, Ziaurrehman Tanoli, et al.
Cancers|June 26, 2020
Safety of BRAF+MEK Inhibitor Combinations: Severe Adverse Event EvaluationTomer Meirson, Nethanel Asher, David Bomze, et al.
Bioinformatics (Oxford, England)|March 15, 2020
κ-helix and the helical lock and key model: a pivotal way of looking at polyproline IITomer Meirson, David Bomze, Gal Markel, et al.
Drug Design, Development and Therapy|July 8, 2017
Virtual screening for potential inhibitors of Mcl-1 conformations sampled by normal modes, molecular dynamics, and nuclear magnetic resonanceYitav Glantz-Gashai, Tomer Meirson, Eli Reuveni, et al.
Pageof 6

Showing results (1-10 of 56) with videos related to

Sort By:
Pageof 6
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|August 5, 2018
Targeting invadopodia for blocking breast cancer metastasisTomer Meirson, Hava Gil-Henn
Accountability in Research|July 2, 2021
The common sense behind clinical trial names: An empirical study of trial acronymsTomer Meirson, Gal Markel, David Bomze
Bioinformatics (Oxford, England)|August 21, 2020
Structural basis of SARS-CoV-2 spike protein induced by ACE2Tomer Meirson, David Bomze, Gal Markel
BMC Gastroenterology|November 18, 2024
Survival outcomes of population-wide colonoscopy screening: reanalysis of the NordICC dataTomer Meirson, Gal Markel, Daniel A Goldstein
Plos Computational Biology|December 22, 2016
Normal Modes Expose Active Sites in EnzymesYitav Glantz-Gashai, Tomer Meirson, Abraham O Samson
Drug Design, Development and Therapy|June 3, 2017
An in silico high-throughput screen identifies potential selective inhibitors for the non-receptor tyrosine kinase Pyk2Tomer Meirson, Abraham O Samson, Hava Gil-Henn
Bioinformatics (Oxford, England)|May 6, 2024
Peptriever: a Bi-Encoder approach for large-scale protein-peptide binding searchRoni Gurvich, Gal Markel, Ziaurrehman Tanoli, et al.
Cancers|June 26, 2020
Safety of BRAF+MEK Inhibitor Combinations: Severe Adverse Event EvaluationTomer Meirson, Nethanel Asher, David Bomze, et al.
Bioinformatics (Oxford, England)|March 15, 2020
κ-helix and the helical lock and key model: a pivotal way of looking at polyproline IITomer Meirson, David Bomze, Gal Markel, et al.
Drug Design, Development and Therapy|July 8, 2017
Virtual screening for potential inhibitors of Mcl-1 conformations sampled by normal modes, molecular dynamics, and nuclear magnetic resonanceYitav Glantz-Gashai, Tomer Meirson, Eli Reuveni, et al.
Pageof 6